GluSense is developing an innovative long-term, injectable continuous glucose sensor for diabetes patients. Glyde CGM is a miniature, long term, implantable continuous glucose monitoring system for both Type 1 and insulin-dependent Type 2 diabetes patients. The system includes a miniature sensor implanted under the skin and an external wearable device. The wearable device reads the glucose signal from the implant and provides basic display and alarms. Data is additionally sent to a smartphone app for additional display and control functions.Founded in 2007, the company is part of the Rainbow Medical innovation house.